Literature DB >> 8620672

The effect of food on the pharmacokinetics of zileuton.

W M Awni1, J H Cavanaugh, G Witt, G R Granneman, L M Dubé.   

Abstract

The present study was undertaken to assess the effect of food on the pharmacokinetic parameters of zileuton. In a nonblinded crossover study, 18 healthy male volunteers who had fasted overnight were randomised to receive a single oral dose of zileuton 600mg in the presence or absence of food consisting of a standardised breakfast on the following morning. The mean zileuton peak plasma concentration (Cmax) increased significantly by 27% after food intake, while the mean area under the plasma concentration versus time curve increased by only 1.4%, a difference that was not statistically significant. The mean time to Cmax was unaffected by the presence of food, as were the other pharmacokinetic parameters assessed. Overall, the results suggest that food has a relatively small effect on the rate of zileuton absorption compared with the fasting state, while the bioavailability of the drug appears to be unaffected. Thus, it is concluded that it is appropriate to administer zileuton with or without food.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8620672     DOI: 10.2165/00003088-199500292-00009

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  10 in total

Review 1.  The effects of food on drug bioavailability.

Authors:  P A Winstanley; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

2.  Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography.

Authors:  G R Granneman; R A Braeckman; K A Erdman
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

3.  The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.

Authors:  S L Wong; W M Awni; J H Cavanaugh; T el-Shourbagy; C S Locke; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

4.  The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.

Authors:  E Israel; R Dermarkarian; M Rosenberg; R Sperling; G Taylor; P Rubin; J M Drazen
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

5.  5-lipoxygenase inhibitory activity of zileuton.

Authors:  G W Carter; P R Young; D H Albert; J Bouska; R Dyer; R L Bell; J B Summers; D W Brooks
Journal:  J Pharmacol Exp Ther       Date:  1991-03       Impact factor: 4.030

6.  The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep.

Authors:  W M Abraham; A Ahmed; A Cortes; M W Sielczak; W Hinz; J Bouska; C Lanni; R L Bell
Journal:  Eur J Pharmacol       Date:  1992-07-07       Impact factor: 4.432

7.  The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.

Authors:  E Israel; P Rubin; J P Kemp; J Grossman; W Pierson; S C Siegel; D Tinkelman; J J Murray; W Busse; A T Segal; J Fish; H B Kaiser; D Ledford; S Wenzel; R Rosenthal; J Cohn; C Lanni; H Pearlman; P Karahalios; J M Drazen
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

8.  Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.

Authors:  C Collawn; P Rubin; N Perez; J Bobadilla; G Cabrera; E Reyes; J Borovoy; D Kershenobich
Journal:  Am J Gastroenterol       Date:  1992-03       Impact factor: 10.864

9.  Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.

Authors:  K P Hui; I K Taylor; G W Taylor; P Rubin; J Kesterson; N C Barnes; P J Barnes
Journal:  Thorax       Date:  1991-03       Impact factor: 9.139

10.  Selective 5-lipoxygenase inhibition in ulcerative colitis.

Authors:  L S Laursen; J Naesdal; K Bukhave; K Lauritsen; J Rask-Madsen
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

  10 in total
  3 in total

Review 1.  Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety.

Authors:  L M Dubé; L J Swanson; W Awni
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 3.  Benefit-risk assessment of antileukotrienes in the management of asthma.

Authors:  Luis García-Marcos; Antje Schuster; Eduardo G Pérez-Yarza
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.